The GPNMB Knockout Ca Ski Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout population derived from the Ca Ski human cervical squamous cell carcinoma line. This product offers a heterogeneous disruption of the GPNMB gene, creating a loss-of-function model suitable for studying the glycoprotein??s role in tumor biology. The polyclonal format minimizes clonal variation effects, enabling robust population-level analyses without the need for single-cell cloning.
The Ca Ski cell line is an adherent epithelial model isolated from a cervical carcinoma metastasis and is positive for human papillomavirus type 16 (HPV-16). This line retains integrated HPV-16 genomes that express the E6 and E7 oncoproteins, which neutralize the p53 and Rb tumor suppressors, respectively. These cells are widely used to study HPV-driven carcinogenesis, providing a clinically relevant background for investigating molecular pathways in cervical cancer.
GPNMB encodes a type I transmembrane glycoprotein that mediates cell adhesion, migration, and immune modulation. It interacts with integrins ??v??3 and ??5??1, CD44, and syndecan-4 to transduce signals via the PI3K/AKT and MAPK/ERK cascades. Downstream, it promotes expression of MMP-9, cyclin D1, Bcl-2, and the transcription factor Snail, driving proliferation, survival, and epithelial?Cmesenchymal transition. GPNMB expression is regulated by MITF, STAT3, NF-??B, TGF-??, EGF, and IL-6, placing it at the intersection of growth factor and cytokine signaling networks.
In cervical cancer, GPNMB overexpression is associated with tumor progression and immune evasion. The Ca Ski knockout model allows researchers to dissect GPNMB??s contributions to HPV-16-driven malignancy, including its effects on cell proliferation, apoptosis resistance, and metastasis. It also provides a platform to study crosstalk between GPNMB and the NF-??B and STAT3 pathways, which are frequently activated in cervical carcinoma.
These polyclonal knockout cells are suitable for multiple cancer biology applications. Functional assays such as MTT proliferation, Transwell migration/invasion, and colony formation can quantify phenotypic changes. Western blotting and flow cytometry enable analysis of AKT/ERK phosphorylation and apoptosis. Co-immunoprecipitation identifies interacting partners, while RNA-seq reveals transcriptomic alterations. Drug sensitivity screens and xenograft models further support therapeutic target validation and biomarker discovery. For technical inquiries, contact Ascent Research.
